Ken Griffin Editas Medicine, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 51,000 shares of EDIT stock, worth $105,060. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,000

Previous 58,000 12.07%

Holding current value

$105,060

Previous $197,000 67.51%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.2 - $3.76 $687,319 - $2.15 Million	572,766 Added 164.0%	922,016 $1.17 Million
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $433,635 - $762,379	127,916 Added 57.79%	349,250 $1.19 Million
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $2.31 Million - $3.6 Million	-494,583 Reduced 69.08%	221,334 $1.03 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $1.3 Million - $2.04 Million	-184,716 Reduced 20.51%	715,917 $5.31 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $3.35 Million - $5.95 Million	535,223 Added 146.47%	900,633 $9.12 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $209,717 - $282,148	30,306 Added 9.04%	365,410 $2.85 Million
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $8.19 Million - $14.8 Million	-1,287,715 Reduced 79.35%	335,104 $2.76 Million
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $5.65 Million - $9.26 Million	803,436 Added 98.05%	1,622,819 $11.8 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $628,060 - $997,196	-75,488 Reduced 8.44%	819,383 $7.27 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $4.41 Million - $7.04 Million	-362,299 Reduced 28.82%	894,871 $11 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $6.73 Million - $14.4 Million	673,181 Added 115.27%	1,257,170 $14.9 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $4.17 Million - $8.18 Million	-296,195 Reduced 33.65%	583,989 $11.1 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $3.71 Million - $5.67 Million	139,676 Added 18.86%	880,184 $23.4 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $21.2 Million - $39.3 Million	538,763 Added 267.05%	740,508 $30.4 Million
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $1.73 Million - $3.13 Million	-55,276 Reduced 21.51%	201,745 $11.4 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $8.57 Million - $19.6 Million	215,869 Added 524.57%	257,021 $10.8 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $3.94 Million - $12.3 Million	-145,594 Reduced 77.96%	41,152 $2.89 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $4.32 Million - $5.72 Million	153,822 Added 467.2%	186,746 $5.24 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $463,388 - $860,148	-25,048 Reduced 43.21%	32,924 $974,000
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $1.44 Million - $3.17 Million	-96,611 Reduced 62.5%	57,972 $1.15 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $465,265 - $778,943	23,872 Added 18.26%	154,583 $4.58 Million
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $4.19 Million - $5 Million	-186,315 Reduced 58.77%	130,711 $2.97 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $5.5 Million - $7.46 Million	268,764 Added 556.89%	317,026 $7.84 Million
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $310,258 - $421,714	-15,968 Reduced 24.86%	48,262 $0
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $417,606 - $729,834	22,958 Added 55.63%	64,230 $1.46 Million
Q3 2018 Nov 13, 2018	SELL	$27.65 - $38.39 $1.29 Million - $1.8 Million	-46,824 Reduced 53.15%	41,272 $0
Q2 2018 Aug 10, 2018	BUY	$31.4 - $41.01 $2.77 Million - $3.61 Million	88,096 New	88,096 $0

Others Institutions Holding EDIT

# of Institutions

225

Shares Held

54.2M

Call Options Held

412K

Put Options Held

355K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $142M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account